Total Payments
$28,685
2024 Payments
$3,867
Companies
59
Transactions
484
Medicare Patients
1,444
Medicare Billing
$204,427
Payment Breakdown by Category
Consulting$14,270 (49.7%)
Food & Beverage$7,586 (26.4%)
Other$5,675 (19.8%)
Education$682.50 (2.4%)
Travel$471.82 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,270 | 11 | 49.7% |
| Food and Beverage | $7,586 | 441 | 26.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,350 | 8 | 11.7% |
| Honoraria | $2,325 | 1 | 8.1% |
| Education | $682.50 | 16 | 2.4% |
| Travel and Lodging | $471.82 | 7 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $8,377 | 35 | $0 (2024) |
| Kite Pharma, Inc. | $3,300 | 2 | $0 (2022) |
| Karyopharm Therapeutics Inc. | $2,325 | 1 | $0 (2020) |
| GENZYME CORPORATION | $1,771 | 13 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $1,739 | 2 | $0 (2020) |
| Seattle Genetics, Inc. | $1,235 | 13 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $969.85 | 44 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $757.50 | 1 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $700.00 | 2 | $0 (2020) |
| Genentech USA, Inc. | $635.30 | 45 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,867 | 22 | AstraZeneca Pharmaceuticals LP ($3,334) |
| 2023 | $574.99 | 2 | GlaxoSmithKline, LLC. ($450.00) |
| 2022 | $2,809 | 8 | Kite Pharma, Inc. ($1,600) |
| 2021 | $1,043 | 7 | GENZYME CORPORATION ($800.00) |
| 2020 | $6,500 | 8 | Karyopharm Therapeutics Inc. ($2,325) |
| 2019 | $1,172 | 57 | GENZYME CORPORATION ($315.00) |
| 2018 | $4,197 | 183 | Seattle Genetics, Inc. ($1,197) |
| 2017 | $8,521 | 197 | AstraZeneca Pharmaceuticals LP ($4,946) |
All Payment Transactions
484 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 10/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/25/2024 | Dr.Reddy's Laboratories,Inc. | — | Consulting Fee | Cash or cash equivalent | $333.00 | General |
| 10/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.84 | General |
| Category: Oncology | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $27.00 | General |
| Category: Oncology | ||||||
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $244.62 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $39.81 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $27.00 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $95.95 | General |
| Category: Oncology | ||||||
| 04/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Oncology | ||||||
| 02/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Oncology | ||||||
| 02/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $100.21 | General |
| Category: Oncology | ||||||
| 01/09/2024 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 04/10/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Oncology | ||||||
| 11/04/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $100.23 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 383 | 542 | $172,975 | $58,681 |
| 2022 | 6 | 389 | 560 | $154,479 | $62,547 |
| 2021 | 8 | 338 | 487 | $102,024 | $49,209 |
| 2020 | 9 | 334 | 449 | $79,950 | $33,991 |
Total Patients
1,444
Total Services
2,038
Medicare Billing
$204,427
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 101 | 185 | $50,875 | $14,639 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 75 | 119 | $41,650 | $13,739 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 66 | 66 | $28,050 | $9,597 | 34.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 36 | $12,960 | $5,325 | 41.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 33 | $11,550 | $4,862 | 42.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 43 | $11,825 | $3,555 | 30.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 25 | $6,125 | $2,717 | 44.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 21 | $3,990 | $2,131 | 53.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $5,950 | $2,115 | 35.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 112 | 113 | $38,895 | $18,592 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 91 | 189 | $42,775 | $14,323 | 33.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 44 | 66 | $19,650 | $7,771 | 39.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 43 | 43 | $16,205 | $6,067 | 37.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 53 | $9,464 | $4,545 | 48.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $8,780 | $3,720 | 42.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 22 | $6,750 | $3,329 | 49.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 28 | $7,140 | $2,621 | 36.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 13 | 24 | $4,820 | $1,579 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 84 | 180 | $31,500 | $14,903 | 47.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 57 | 57 | $19,095 | $8,829 | 46.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 48 | 59 | $13,865 | $7,090 | 51.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 37 | 38 | $12,350 | $6,583 | 53.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 36 | 53 | $9,540 | $4,013 | 42.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 26 | $5,720 | $3,059 | 53.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 50 | $6,000 | $2,587 | 43.1% |
About Dr. Michael Rotkowitz, M.D
Dr. Michael Rotkowitz, M.D is a Hematology & Oncology healthcare provider based in Sewell, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1649436973.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Rotkowitz, M.D has received a total of $28,685 in payments from pharmaceutical and medical device companies, with $3,867 received in 2024. These payments were reported across 484 transactions from 59 companies. The most common payment nature is "Consulting Fee" ($14,270).
As a Medicare-enrolled provider, Rotkowitz has provided services to 1,444 Medicare beneficiaries, totaling 2,038 services with total Medicare billing of $204,427. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Sewell, NJ
- Active Since 08/06/2008
- Last Updated 08/23/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1649436973
Products in Payments
- TAGRISSO (Drug) $5,392
- Tecartus (Drug) $3,300
- XPOVIO (Drug) $2,325
- ONIVYDE (Drug) $1,736
- IMFINZI (Biological) $1,463
- Adcetris (Biological) $1,152
- RYBREVANT (Drug) $757.50
- OPDIVO (Biological) $735.32
- ELITEK (Drug) $639.01
- ZEJULA (Drug) $628.09
- LIBTAYO (Biological) $447.68
- CABLIVI (Biological) $400.00
- ELITEK (Biological) $400.00
- NO PRODUCT DISCUSSED (Drug) $400.00
- JEVTANA (Drug) $300.00
- Avastin (Biological) $262.79
- IMBRUVICA (Drug) $239.62
- Revlimid (Drug) $192.76
- KEYTRUDA (Biological) $162.96
- CYRAMZA (Drug) $156.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.